Sugi Predict

Sugi Predict / Compounds / SCHEMBL8102792

SCHEMBL8102792

SCHEMBL8102792

COc1ccc(NC(=O)C(C)(C)C)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.73
▸ CYP2C19 P33261 2/20 0.73
▸ CYP2C9 P11712 1/20 0.73
▸ IMPDH2 P12268 1/20 0.65
▸ IMPDH1 P20839 1/20 0.65
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ MAPT P10636 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ TP53 P04637 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ TRPV1 Q8NER1 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28684668 0.87 CYP1A2 (0.56) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL9447193 0.87 CYP1A2 (0.56) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL5414824 0.87 CYP1A2 (0.57) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL30223469 0.85 CYP1A2 (0.59) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL7426198 0.85 CYP1A2 (0.55) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL1285002 0.85 CYP1A2 (0.59) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL344338 0.85 GRM4 (0.57) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL4440336 0.85 CYP1A2 (1.00) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL6926944 0.85 CYP1A2 (0.71) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1
SCHEMBL9430839 0.84 CYP1A2 (0.54) CYP1A2CYP2C19CYP2C9IMPDH2IMPDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0216469-A2 Process for the preparation of 5,6-dialkoxyanthranilic acids ORTHO PHARMACEUTICAL CORPORATION (US) 1987-04-01 — — EP claimed
CN-113912529-B Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium 成都大学 2023-07-25 — — CN disclosed
CN-113912529-A Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium 成都大学 2022-01-11 — — CN disclosed
US-8329726-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-12-11 — — US disclosed
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC. 2012-04-05 — — US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 — — US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 — — US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 — — US disclosed
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2008-03-13 — — US disclosed
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity METHYLGENE, INC. (CA) 2008-01-03 — — US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 — — US disclosed
EP-0212868-B1 PROCESS FOR PREPARING 2-ACYL-3,4-DIALKOXYANILINES ORTHO PHARMACEUTICAL CORPORATION (US) 1989-12-13 — — EP disclosed
US-4883787-A Process for preparing 2-acyl-3, 4-dialkoxyanilines ORTHO PHARMACEUTICAL CORPORATION (US) 1989-11-28 — — US disclosed
US-4731480-A Process for preparing 2-acyl-3,4-dialkoxyanilines ORTHO PHARMACEUTICAL CORPORATION (US) 1988-03-15 — — US disclosed
US-4658054-A Process for the preparation of 5,6-dialkoxyanthranilic acids ORTHO PHARMACEUTICAL CORPORATION (US) 1987-04-14 — — US disclosed
EP-0216469-A2 Process for the preparation of 5,6-dialkoxyanthranilic acids ORTHO PHARMACEUTICAL CORPORATION (US) 1987-04-01 — — EP disclosed
EP-0212868-A1 Process for preparing 2-acyl-3,4-dialkoxyanilines ORTHO PHARMACEUTICAL CORPORATION (US) 1987-03-04 — — EP disclosed
EP-0211588-A1 Process for preparing 2-acyl-3,4-dialkoxyanilines ORTHO PHARMACEUTICAL CORPORATION (US) 1987-02-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 CYP1A2 4222/4885CYP2C19 4590/4885CYP2C9 4759/4885
US-20120083482-A1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING HGF, MET, KDR CYP1A2 643/4885CYP2C19 1601/4885CYP2C9 1518/4885
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF ABL1, MAP3K20, MAP3K1 CYP1A2 3990/4885CYP2C19 3617/4885CYP2C9 4129/4885
US-20080064718-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET CYP1A2 4345/4885CYP2C19 4235/4885CYP2C9 4358/4885
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 CYP1A2 2939/4885CYP2C19 3372/4885CYP2C9 1816/4885
US-20080004273-A1 Inhibitors of protein tyrosine kinase activity HGF, ERBB2, MET CYP1A2 4345/4885CYP2C19 4235/4885CYP2C9 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.